163 related articles for article (PubMed ID: 21747065)
1. Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?
Waxman AB
Circulation; 2011 Jul; 124(2):133-5. PubMed ID: 21747065
[No Abstract] [Full Text] [Related]
2. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Guazzi M; Vicenzi M; Arena R; Guazzi MD
Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
[TBL] [Abstract][Full Text] [Related]
3. Letter by Jamous regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Jamous FG
Circulation; 2012 Feb; 125(8):e407; author reply e409-10. PubMed ID: 22371449
[No Abstract] [Full Text] [Related]
4. Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Forfia PR; Borlaug BA
Circulation; 2012 Feb; 125(8):e408; author reply e409-10. PubMed ID: 22371450
[No Abstract] [Full Text] [Related]
5. Letter by Gordon et al regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Gordon B; McDiarmid A; MacGowan G
Circulation; 2012 Feb; 125(8):e406; author reply e409-10. PubMed ID: 22371448
[No Abstract] [Full Text] [Related]
6. [Oral sildenafil for pulmonary hypertension in neonates].
Gutiérrez Nicolás F; Viña Romero MM; González Carretero P; Merino Alonso J
Farm Hosp; 2011; 35(3):157-8. PubMed ID: 21439880
[No Abstract] [Full Text] [Related]
7. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
Guazzi M; Vicenzi M; Arena R
Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
Cooper TJ; Guazzi M; Al-Mohammad A; Amir O; Bengal T; Cleland JG; Dickstein K
Eur J Heart Fail; 2013 Jan; 15(1):119-22. PubMed ID: 23097067
[TBL] [Abstract][Full Text] [Related]
11. Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine.
Karakitsos D; Papanikolaou J; Karabinis A; Alalawi R; Wachtel M; Jumper C; Alexopoulos D; Davlouros P
Int J Cardiol; 2013 Aug; 167(3):848-54. PubMed ID: 22386699
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction: diagnosis and management.
Ohara T; Ohte N; Little WC
Curr Opin Cardiol; 2012 May; 27(3):281-7. PubMed ID: 22450719
[TBL] [Abstract][Full Text] [Related]
13. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
Behling A; Rohde LE; Colombo FC; Goldraich LA; Stein R; Clausell N
J Card Fail; 2008 Apr; 14(3):189-97. PubMed ID: 18381181
[TBL] [Abstract][Full Text] [Related]
14. [Potentially deadly: warning about Revatio (sildenafil) taken with nitroglycerine].
Sabourin G
Perspect Infirm; 2010; 7(5):42. PubMed ID: 21744634
[No Abstract] [Full Text] [Related]
15. Intraoperative oral sildenafil for management of pulmonary hypertension: a stepping stone to the future.
Augoustides JG
J Thorac Cardiovasc Surg; 2007 Jul; 134(1):267; author reply 267-8. PubMed ID: 17599538
[No Abstract] [Full Text] [Related]
16. How long can we leave patients with pulmonary arterial hypertension on oral drug monotreatment?
Ogawa A; Matsubara H
Circ J; 2012; 76(5):1089-90. PubMed ID: 22466634
[No Abstract] [Full Text] [Related]
17. "Out of the blue"-safety and efficacy of pulmonary hypertension treatment in childhood*.
Kraemer U; Wildschuth E; Tibboel D
Pediatr Crit Care Med; 2014 May; 15(4):377-8. PubMed ID: 24801422
[No Abstract] [Full Text] [Related]
18. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives.
Guazzi M
Circ Heart Fail; 2014 Mar; 7(2):367-77. PubMed ID: 24643889
[No Abstract] [Full Text] [Related]
20. Sildenafil improves clinical and functional status of an elderly postmenopausal female with 'out of proportion' PH associated with left heart disease.
Correale M; Totaro A; Ferraretti A; Di Biase M; Brunetti ND
Monaldi Arch Chest Dis; 2013 Dec; 80(4):193-4. PubMed ID: 25087297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
